Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
RAD001(everolimus)
DRUG
2 trials
Sponsors
Bayside Health
, Novartis Pharmaceuticals
Conditions
Acute Myeloid Leukemia
Adenocarcinoma
Carcinoma
Hypernephroid
Nephroid Carcinoma
Renal Cell
Phase 1
Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia
NCT00636922
Bayside Health
Acute Myeloid Leukemia
Start: 2010-02-28
End: 2014-01-31
Target: 40
Updated: 2013-02-15
Phase 2
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Completed
NCT00719264
Novartis Pharmaceuticals
Adenocarcinoma, Carcinoma, Hypernephroid +2
Start: 2008-11-12
End: 2013-04-15
Updated: 2017-03-20
Related Papers
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.
2015-04-07
59 citations